浙江省科技型企业---加速您的多肽研究
首页 >多肽产品 >Bax抑制剂多肽 Bax inhibitor peptide V5

多肽产品

Bax抑制剂多肽 Bax inhibitor peptide V5,H2N-Val-Pro-Met-Leu-Lys-COOH,H2N-VPMLK-OH,杭州专肽生物的产品

Bax抑制剂多肽 Bax inhibitor peptide V5

Bax抑制剂肽V5醋酸盐是Bax介导的细胞凋亡抑制剂,是Bcl-2家族蛋白的促凋亡成员,在线粒体依赖性细胞凋亡中发挥重要作用。用于癌症治疗。

编号:429548

CAS号:579492-81-2/2760881-58-9

单字母:H2N-VPMLK-OH

纠错
  • 编号:429548
    中文名称:Bax抑制剂多肽 Bax inhibitor peptide V5
    英文名:Bax inhibitor peptide V5
    CAS号:579492-81-2,free base
    2760881-58-9,醋酸盐
    单字母:H2N-VPMLK-OH
    三字母:H2N

    N端氨基

    -Val

    缬氨酸

    -Pro

    脯氨酸

    -Met

    甲硫氨酸

    -Leu

    亮氨酸

    -Lys

    赖氨酸

    -OH

    C端羧基

    氨基酸个数:5
    分子式:C27H50N6O6S1
    平均分子量:586.79
    精确分子量:586.35
    等电点(PI):-
    pH=7.0时的净电荷数:1.97
    平均亲水性:-0.4
    疏水性值:0.88
    消光系数:-
    标签:抑制剂相关肽(Inhibitor Peptide)    癌症研究肽   

  • Bax inhibitor peptide V5(BIP V5)是抑制Bax蛋白易位到线粒体中的肽类抑制剂。

    Bax是Bcl-2蛋白家族的促凋亡成员,在线粒体依赖性细胞凋亡中起着重要作用。Bax存在于细胞质中,接受细胞凋亡刺激后转移到线粒体中。

    BIP V5是细胞膜渗透性的肽类抑制剂,抑制Bax易位到线粒体中。在HeLa细胞中,BIP V5保护细胞免受UVC和STS诱导的细胞凋亡。在U87-MG胶质瘤细胞、MCF-7乳腺癌细胞和LNCaP前列腺癌细胞中,BIP V5也抑制由抗癌药顺铂、依托泊苷和阿霉素诱导的细胞凋亡。在缺乏Bax的细胞(DU145)中,BIP V5不能抑制UVC或STS诱导的细胞凋亡,这表明BIP V5仅抑制Bax蛋白介导的细胞凋亡。同样地,经UVC照射和STS治疗后,BIP(V5)抑制Bax易位到线粒体中。由细胞凋亡刺激引发的线粒体细胞色素c释放以及caspase激活显著地受BIP V5抑制。BIP V5呈剂量依赖性地抑制Ku70与内源性Bax蛋白间相互作用。

    在小鼠模型中,BIP V5分别增加超过11倍和3倍的抗凋亡蛋白XIAP和Bcl-2表达,并减少了10%、30%和约50%的细胞凋亡诱导的蛋白表达,包括Bax、Bad以及NF-κB p65。另外,BIP V5增加葡萄糖响应性胰岛素分泌。

    Bax抑制剂肽V5醋酸盐是Bax介导的细胞凋亡抑制剂,是Bcl-2家族蛋白的促凋亡成员,在线粒体依赖性细胞凋亡中发挥重要作用。用于癌症治疗。

    Bax inhibitor peptide V5 acetate, a Bax-mediated apoptosis inhibitor, is a pro-apoptotic member of Bcl-2 family proteins and plays an important role in mitochondria-dependent apoptosis. It is used in cancer treatment.

    定义
    酶是用于生化反应的非常有效的催化剂。它们通过提供较低活化能的替代反应途径来加快反应速度。酶作用于底物并产生产物。一些物质降低或什至停止酶的催化活性被称为抑制剂。
    发现
    1965年,Umezawa H分析了微生物产生的酶抑制剂,并分离出了抑制亮肽素和抗痛药的胰蛋白酶和木瓜蛋白酶,乳糜蛋白酶抑制的胰凝乳蛋白酶,胃蛋白酶抑制素抑制胃蛋白酶,泛磷酰胺抑制唾液酸酶,乌藤酮抑制酪氨酸羟化酶,多巴汀抑制多巴胺3-羟硫基嘧啶和多巴胺3-羟色胺酶酪氨酸羟化酶和多巴胺J3-羟化酶。最近,一种替代方法已应用于预测新的抑制剂:合理的药物设计使用酶活性位点的三维结构来预测哪些分子可能是抑制剂1。已经开发了用于识别酶抑制剂的基于计算机的方法,例如分子力学和分子对接。
    结构特征
    已经确定了许多抑制剂的晶体结构。已经确定了三种与凝血酶复合的高效且选择性的低分子量刚性肽醛醛抑制剂的晶体结构。这三种抑制剂全部在P3位置具有一个新的内酰胺部分,而对胰蛋白酶选择性最高的两种抑制剂在P1位置具有一个与S1特异性位点结合的胍基哌啶基。凝血酶的抑制动力学从慢到快变化,而对于胰蛋白酶,抑制的动力学在所有情况下都快。根据两步机理2中稳定过渡态络合物的缓慢形成来检验动力学。
    埃米尔•菲舍尔(Emil Fischer)在1894年提出,酶和底物都具有特定的互补几何形状,彼此恰好契合。这称为“锁和钥匙”模型3。丹尼尔·科什兰(Daniel Koshland)提出了诱导拟合模型,其中底物和酶是相当灵活的结构,当底物与酶4相互作用时,活性位点通过与底物的相互作用不断重塑。
    在众多生物活性肽的成熟过程中,需要由其谷氨酰胺(或谷氨酰胺)前体形成N末端焦谷氨酸(pGlu)。游离形式并与底物和三种咪唑衍生抑制剂结合的人QC的结构揭示了类似于两个锌外肽酶的α/β支架,但有多个插入和缺失,特别是在活性位点区域。几种活性位点突变酶的结构分析为针对QC相关疾病5的抑制剂的合理设计提供了结构基础。
    作用方式
    酶是催化化学反应的蛋白质。酶与底物相互作用并将其转化为产物。抑制剂的结合可以阻止底物进入酶的活性位点和/或阻止酶催化其反应。抑制剂的种类繁多,包括:非特异性,不可逆,可逆-竞争性和非竞争性。可逆抑制剂 以非共价相互作用(例如疏水相互作用,氢键和离子键)与酶结合。非特异性抑制方法包括最终使酶的蛋白质部分变性并因此不可逆的任何物理或化学变化。特定抑制剂 对单一酶发挥作用。大多数毒药通过特异性抑制酶发挥作用。竞争性抑制剂是任何与底物的化学结构和分子几何结构非常相似的化合物。抑制剂可以在活性位点与酶相互作用,但是没有反应发生。非竞争性抑制剂是与酶相互作用但通常不在活性位点相互作用的物质。非竞争性抑制剂的净作用是改变酶的形状,从而改变活性位点,从而使底物不再能与酶相互作用而产生反应。非竞争性抑制剂通常是可逆的。不可逆抑制剂与酶形成牢固的共价键。这些抑制剂可以在活性位点附近或附近起作用。
    功能
    工业应用中, 酶在商业上被广泛使用,例如在洗涤剂,食品和酿造工业中。蛋白酶用于“生物”洗衣粉中,以加速蛋白质在诸如血液和鸡蛋等污渍中的分解。商业上使用酶的问题包括:它们是水溶性的,这使得它们难以回收,并且一些产物可以抑制酶的活性(反馈抑制)。
    药物分子,许多药物分子都是酶抑制剂,药用酶抑制剂通常以其特异性和效力为特征。高度的特异性和效力表明该药物具有较少的副作用和较低的毒性。酶抑制剂在自然界中发现,并且也作为药理学和生物化学的一部分进行设计和生产6。
    天然毒物 通常是酶抑制剂,已进化为保护植物或动物免受天敌的侵害。这些天然毒素包括一些已知最剧毒的化合物。
    神经气体( 例如二异丙基氟磷酸酯(DFP))通过与丝氨酸的羟基反应生成酯,从而抑制了乙酰胆碱酯酶的活性位点。
    参考
    1、Scapin G (2006). Structural biology and drug discovery. Curr. Pharm. Des.,      12(17):2087–2097.
    2、Krishnan R, Zhang E, Hakansson K, Arni RK, Tulinsky A, Lim-Wilby MS, Levy OE, Semple JE, Brunck TK (1998). Highly selective mechanism-based thrombin inhibitors:  structures of thrombin and trypsin inhibited with rigid peptidyl aldehydes. Biochemistry, 37 (35):12094-12103.
    3、Fischer E (1894). Einfluss der configuration auf die wirkung der enzyme. Ber. Dt. Chem. Ges., 27:2985–2993.
    4、Koshland DE (1958). Application of a theory of enzyme specificity to protein synthesis. PNAS., 44 (2):98–104.
    5、Huang KF, Liu YL, Cheng WJ, Ko TP, Wang AH (2005). Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation. PNAS., 102(37):13117-13122.
    6、Holmes CF, Maynes JT, Perreault KR, Dawson JF, James MN (2002). Molecular enzymology underlying regulation of protein phosphatase-1 by natural toxins. Curr Med Chem., 9(22):1981-1989.

     

    Definition
    Enzymes are very efficient catalysts for biochemical reactions. They speed up reactions by providing an alternative reaction pathway of lower activation energy. Enzyme acts on substrate and gives rise to a product. Some substances reduce or even stop the catalytic activities of enzymes are called inhibitors.

    Discovery
    In 1965, Umezawa H analysed enzyme inhibitors produced by microorganisms and isolated leupeptin and antipain inhibiting trypsin and papain, chymostatin inhibiting chymotrypsin, pepstatin inhibiting pepsin, panosialin inhibiting sialidases, oudenone inhibiting tyrosine hydroxylase, dopastin inhibiting dopamine 3-hydroxylase, aquayamycin and chrothiomycin inhibiting tyrosine hydroxylase and dopamine J3-hydroxylase . Recently, an alternative approach has been applied to predict new inhibitors: rational drug design uses the three-dimensional structure of an enzyme's active site to predict which molecules might be inhibitors 1. Computer-based methods for identifying inhibitor for an enzyme have been developed, such as molecular mechanics and molecular docking.

    Structural Characteristics
    The crystal structures of many inhibitors have been determined. The crystal structures of three highly potent and selective low-molecular weight rigid peptidyl aldehyde inhibitors complexed with thrombin have been determined. All the three inhibitors have a novel lactam moiety at the P3 position, while the two with greatest trypsin selectivity have a guanidinopiperidyl group at the P1 position that binds in the S1 specificity site. The kinetics of inhibition vary from slow to fast with thrombin and are fast in all cases with trypsin. The kinetics are examined in terms of the slow formation of a stable transition-state complex in a two-step mechanism 2.

    Emil Fischer in 1894 suggested that both the enzyme and the substrate possess specific complementary geometric shapes that fit exactly into one another.This is known as "the lock and key" model 3. Daniel Koshland suggested induced fit model where substrate and enzymes are rather flexible structures, the active site is continually reshaped by interactions with the substrate as the substrate interacts with the enzyme 4.

    N-terminal pyroglutamate (pGlu) formation from its glutaminyl (or glutamyl) precursor is required in the maturation of numerous bioactive peptides. The structure of human QC in free form and bound to a substrate and three imidazole-derived inhibitors reveals an alpha/beta scaffold akin to that of two-zinc exopeptidases but with several insertions and deletions, particularly in the active-site region. The structural analyses of several active-site-mutant enzymes provide a structural basis for the rational design of inhibitors against QC-associated disorders 5.

    Mode of Action
    Enzymes are proteins that catalyze chemical reactions. Enzymes interact with substrate and convert them into products. Inhibitor binding can stop a substrate from entering the enzyme's active site and/or hinder the enzyme from catalyzing its reaction. There are a variety of types of inhibitors including: nonspecific, irreversible, reversible - competitive and noncompetitive. Reversible inhibitors bind to enzymes with non-covalent interactions like hydrophobic interactions, hydrogen bonds, and ionic bonds. Non-specific methods of inhibition include any physical or chemical changes which ultimately denature the protein portion of the enzyme and are therefore irreversible. Specific Inhibitors exert their effects upon a single enzyme. Most poisons work by specific inhibition of enzymes. A competitive inhibitor is any compound which closely resembles the chemical structure and molecular geometry of the substrate. The inhibitor may interact with the enzyme at the active site, but no reaction takes place. A noncompetitive inhibitor is a substance that interacts with the enzyme, but usually not at the active site.  The net effect of a non competitive inhibitor is to change the shape of the enzyme and thus the active site, so that the substrate can no longer interact with the enzyme to give a reaction. Non competitive inhibitors are usually reversible. Irreversible Inhibitors form strong covalent bonds with an enzyme.  These inhibitors may act at, near, or remote from the active site .

    Functions
    Industrial application, enzymes are widely used commercially, for example in the detergent, food and brewing industries. Protease enzymes are used in 'biological' washing powders to speed up the breakdown of proteins in stains like blood and egg. Problems using enzymes commercially include: they are water soluble which makes them hard to recover and some products can inhibit the enzyme activity (feedback inhibition) .

    Drug molecules, many drug molecules are enzyme inhibitors and a medicinal enzyme inhibitor is usually characterized by its specificity and its potency. A high specificity and potency suggests that a drug will have fewer side effects and less toxic. Enzyme inhibitors are found in nature and are also designed and produced as part of pharmacology and biochemistry 6.

    Natural poisons are often enzyme inhibitors that have evolved to defend a plant or animal against predators. These natural toxins include some of the most poisonous compounds known.

    Nerve gases such as diisopropylfluorophosphate (DFP) inhibit the active site of acetylcholine esterase by reacting with the hydroxyl group of serine to make an ester.

    References

    Scapin G (2006). Structural biology and drug discovery. Curr. Pharm. Des.,      12(17):2087–2097.

    Krishnan R, Zhang E, Hakansson K, Arni RK, Tulinsky A, Lim-Wilby MS, Levy OE, Semple JE, Brunck TK (1998). Highly selective mechanism-based thrombin inhibitors:  structures of thrombin and trypsin inhibited with rigid peptidyl aldehydes. Biochemistry, 37 (35):12094-12103.

    Fischer E (1894). Einfluss der configuration auf die wirkung der enzyme. Ber. Dt. Chem. Ges., 27:2985–2993.

    Koshland DE (1958). Application of a theory of enzyme specificity to protein synthesis. PNAS., 44 (2):98–104.

    Huang KF, Liu YL, Cheng WJ, Ko TP, Wang AH (2005). Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation. PNAS., 102(37):13117-13122.

    Holmes CF, Maynes JT, Perreault KR, Dawson JF, James MN (2002). Molecular enzymology underlying regulation of protein phosphatase-1 by natural toxins. Curr Med Chem., 9(22):1981-1989.

    化学预防肽是有助于预防疾病(例如癌症或糖尿病)的发作或发展的肽。这些肽可以源自天然来源,例如大豆或牛奶,也可以来自肽模拟物的设计,也可以源自使用合成肽进行的肽筛选。据认为,这些肽中的某些可以充当细胞周期的调节剂,其调节使细胞通过复制周期前进所需的蛋白质的产生和功能。另外,现在有越来越多的证据表明特定的饮食模式,食物和饮料以及其他饮食物质可以而且确实可以预防癌症。越来越多的流行病学研究表明,食物,营养和身体活动在预防和改变癌症过程中很重要。包括植物蛋白酶抑制剂,乳铁蛋白,乳铁蛋白,凝集素和lunasin在内的不同类型的食物蛋白和多肽似乎起着化学预防剂的作用。如今,蛋白质和多肽被认为是一组营养保健品,在预防癌症的不同阶段(包括起始,促进和进展)方面显示出潜力。此外,已经发现在植物中发现的一些蛋白酶抑制剂,例如豆类和大豆,是有效的癌发生抑制剂。致癌作用是引发和促进癌症的过程。 Bowman-Birk抑制剂和Kunitz胰蛋白酶抑制剂就在其中。目前,这些化合物在致癌作用中的生物学功能主要归因于抑制癌细胞的侵袭和转移,但是,其作用机理仍不完全清楚,需要进一步研究以充分阐明它们。

  • DOI名称
    10.2337/db06-1679Cell-permeable pentapeptide V5 inhibits apoptosis and enhances insulin secretion下载
    10.1038/ncb955Cytoprotective membrane-permeable peptides designed from the Bax-binding domain of Ku70下载
  • 暂时没有数据
  • 暂时没有数据